Director/PDMR Shareholding

Destiny Pharma PLC

04 October 2023

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 4 October 2023 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and treat life threatening infections, announces that it was notified on 4 October 2023 that on 29 September 2023, Dr William Love, Chief Scientific Officer of the Company, transferred 2,300,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to his wife, a PCA, by way of gift for nil consideration.

Following the transfer, Dr William Love's beneficial interest in the Company remains unchanged at 6,509,500 Ordinary Shares, representing 6.83 per cent. of the total issued share capital.

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

[phone]

[e-mail]

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

For further information on the Company, please visit www.destinypharma.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr William Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Transfer of Ordinary Shares, by way of gift, to Carol Love, a Person Closely Associated with him, for nil consideration.
c)	Price(s) and volume(s)	0 (gift)  2,300,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	29 September 2023
f)	Place of the transaction	Off-Market

 

END